| |
| |
|
| Insider
Information: |
Heyman Richard A. |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
249,549 |
|
|
Indirect Shares
|
253,679 |
|
|
| Direct
Value |
$4,221 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
503,228 |
|
|
| Total
Value |
$4,221 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Receptos, Inc. |
RCPT |
Director |
2015-08-27 |
0 |
2015-05-28 |
0 |
Premium* |
|
|
Oric Pharmaceuticals, Inc. |
ORIC |
Director |
2021-09-15 |
12,500 |
2021-09-15 |
216,272 |
Premium* |
|
|
Tango Therapeutics Ord Shs |
TNGX |
Director |
2020-09-02 |
40,600 |
|
0 |
Premium* |
|
|
Metacrine, Inc. |
MTCR |
Director |
2020-09-15 |
51,177 |
|
0 |
Premium* |
|
|
Kineta Ord Shs |
KA |
Director |
2021-02-01 |
8,117 |
2020-12-22 |
0 |
Premium* |
|
|
Pmv Pharmaceuticals, Inc. |
PMVP |
Director |
2021-06-01 |
0 |
2021-06-01 |
0 |
Premium* |
|
|
Enliven Therapeutics Ord Shs |
ELVN |
|
2024-04-15 |
137,155 |
2024-04-15 |
37,407 |
Premium* |
|
|
Rayzebio, Inc. |
RYZB |
|
2024-02-26 |
0 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
42 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ELVN |
Enliven Therapeutics Ord ... |
Director |
– • – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
I/I |
68,579 |
31,172 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Director |
– • – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
149,820 |
149,820 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Director |
– • – |
2023-12-19 |
4 |
AS |
$13.00 |
$3,315 |
D/D |
(255) |
149,565 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Director |
– • – |
2023-12-20 |
4 |
AS |
$13.02 |
$24,939 |
I/I |
(1,915) |
29,257 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Director |
– • – |
2023-12-20 |
4 |
AS |
$13.02 |
$27,473 |
D/D |
(2,110) |
147,455 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Director |
– • – |
2023-12-21 |
4 |
AS |
$13.00 |
$78 |
I/I |
(6) |
29,251 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Director |
– • – |
2023-12-21 |
4 |
AS |
$13.00 |
$91 |
D/D |
(7) |
147,448 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Director |
– • – |
2023-12-22 |
4 |
AS |
$13.00 |
$455 |
I/I |
(35) |
29,216 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
Director |
– • – |
2023-12-22 |
4 |
AS |
$13.00 |
$2,184 |
D/D |
(168) |
147,280 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-01-30 |
4 |
AS |
$16.41 |
$20,840 |
D/D |
(1,270) |
146,010 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-02-15 |
4 |
AS |
$17.42 |
$22,117 |
D/D |
(1,270) |
144,740 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-03-19 |
4 |
AS |
$14.50 |
$18,419 |
D/D |
(1,270) |
143,470 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-11 |
4 |
AS |
$25.03 |
$126,279 |
D/D |
(5,045) |
138 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-11 |
4 |
AS |
$25.00 |
$16,225 |
I/I |
(649) |
28,567 |
0 |
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-15 |
4 |
AS |
$19.94 |
$25,383 |
D/D |
(1,270) |
137,155 |
0 |
- |
|
| KA |
Kineta Ord Shs |
Director |
– • – |
2020-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,158 |
6,158 |
0 |
- |
|
| KA |
Kineta Ord Shs |
Director |
– • – |
2021-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
1,959 |
8,117 |
0 |
- |
|
| MTCR |
Metacrine, Inc. |
Director |
– • – |
2020-09-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
51,177 |
|
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • – |
2020-04-23 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
165,000 |
|
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • – |
2020-04-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,500 |
|
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • – |
2020-04-28 |
4 |
A |
$0.00 |
$0 |
I/I |
62,500 |
227,500 |
0 |
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • – |
2021-04-28 |
4 |
AS |
$25.08 |
$2,508 |
I/I |
(100) |
227,300 |
0 |
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • – |
2021-04-30 |
4 |
AS |
$25.26 |
$2,526 |
I/I |
(100) |
227,200 |
0 |
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • – |
2021-05-11 |
4 |
AS |
$25.11 |
$2,511 |
I/I |
(100) |
227,100 |
0 |
- |
|
| ORIC |
Oric Pharmaceuticals, Inc... |
Director |
– • – |
2021-05-14 |
4 |
AS |
$25.31 |
$81,382 |
I/I |
(3,215) |
223,885 |
0 |
- |
|
42 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
